Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594 | 0.93 | EPAS1 (0.33) | EPAS1HTR2C | |
| SCHEMBL26123900 | 0.91 | MBTD1 (0.35) | EPAS1 | |
| Hydrochloric Acid SCHEMBL28169201 | 0.91 | EPAS1 (0.32) | EPAS1HTR2C | |
| SCHEMBL20121932 | 0.90 | CXCR4 (0.31) | EPAS1ALDH1A1 | |
| SCHEMBL5680966 | 0.89 | EPAS1 (0.35) | EPAS1 | |
| SCHEMBL20256032 | 0.89 | EPAS1 (0.35) | EPAS1HTR2CALDH1A1 | |
| SCHEMBL2273760 | 0.84 | MBTD1 (0.40) | — | |
| SCHEMBL13351747 | 0.84 | MBTD1 (0.36) | EPAS1 | |
| SCHEMBL9142378 | 0.84 | MBTD1 (0.40) | — | |
| SCHEMBL943033 | 0.84 | EPAS1 (0.33) | EPAS1HTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| US-8399450-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-03-19 | — | — | US | disclosed |
| US-8377921-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-19 | — | — | US | disclosed |
| US-8372858-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-02-12 | — | — | US | disclosed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | disclosed |
| EP-2537830-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-12-26 | — | — | EP | disclosed |
| US-20110257154-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
| US-20110257154-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
| US-20110257155-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | EPAS1 1490/4885HTR2C 4403/4885ALDH1A1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.